title: Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
abstract: We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis. Clinical benefits and CT healing were obtained within 2 months of teriparatide initiation and denosumab withdrawal. Increase in bone turnover previously described, when denosumab treatment is removed, might have a synergistic effect to the stimulating effect of teriparatide on bone remodeling to promptly heal osteonecrosis of the jaw.
authors.affiliation: Belgium and Bone and Cartilage Metabolism Unit, Department of Public Health, Epidemiology and Health Economics , University of Liège, CHU, Liège, Belgium, audrey.neuprez@chu.ulg.ac.be.
authors.forename: Audrey
authors.initials: A
authors.lastname: Neuprez
authors.forename: E
authors.initials: E
authors.lastname: Rompen
authors.forename: J M
authors.initials: JM
authors.lastname: Crielaard
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D000069448:Denosumab; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D056687:Off-Label Use; D010020:Osteonecrosis / Q000139:chemically induced* / Q000188:drug therapy*; D010024:Osteoporosis / Q000188:drug therapy; D019379:Teriparatide / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D019379:Teriparatide; D000069448:Denosumab